Effectiveness and safety of labetalol with magnesium sulfate in preeclampsia patients and its effect on maternal and fetal outcomes: a prospective observational study at a tertiary care teaching hospital in central India

Archishna R.  Meshram; Ritu R. Kerketta; Chetna A. Shamkuwar

doi:10.18203/2320-1770.ijrcog20263985

Authors

Archishna R. Meshram Government Medical College, Hanuman Nagar, Medical Square, Nagpur, Maharashtra, India
Ritu R. Kerketta Department of Pharmacology, Government Medical College, Hanuman Nagar, Medical Square, Nagpur, Maharashtra, India
Chetna A. Shamkuwar Department of Pharmacology, Government Medical College, Complex Area, Mul Road, Gadchiroli, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20263985

Keywords:

Preeclampsia, Labetalol, Magnesium sulfate, Maternal outcome, Fetal outcome

Abstract

Background: Preeclampsia is a major contributor to maternal and neonatal morbidity and mortality, particularly in developing countries. Labetalol and magnesium sulfate are commonly used for blood pressure control and seizure prophylaxis, respectively. However, evidence regarding their combined effectiveness in routine clinical practice in Central India remains limited.

Methods: A prospective observational study was conducted from October to December 2025, including 50 women with preeclampsia and 50 women without preeclampsia. Blood pressure in preeclampsia patients was recorded at baseline, 1 hour, and 4 hours after combined therapy, along with serum total protein levels measured before and after treatment. Maternal and fetal outcomes, along with adverse drug reactions, were assessed up to 48 hours postpartum.

Results: Among the preeclampsia group, systolic and diastolic blood pressure decreased significantly (p<0.0001) following treatment, and total serum protein levels increased after treatment. Compared to the non-preeclampsia group, the preeclampsia group exhibited higher rates of low birth weight (82% versus 36%), preterm birth (68% versus 18%) and cesarean delivery was more frequent (76% versus 66%) but not significant (p=0.378). Adverse drug reactions were mild.

Conclusions: Combined therapy was associated with effective short-term blood pressure control; however, adverse maternal and fetal outcomes were observed in women with preeclampsia.

References

American College of Obstetricians and Gynecologists. Gestational hypertension and preeclampsia. ACOG Practice Bulletin No. 222. Obstet Gynecol. 2020;135(6):e237–e260.

Uzan J, Carbonnel M, Piconne O, Asmar R, Ayoubi JM. Pre-eclampsia: pathophysiology, diagnosis, and management. Vasc Health Risk Manag. 2011;7:467–74.

Khan B, Yar RA, Khakwani AK, Karim S, Ali HA. Preeclampsia incidence and its maternal and neonatal outcomes with associated risk factors. Cureus. 2022;14(11):e31143.

Swetha R, Reddy MP, Mubina S. Comparative evaluation of Pritchard’s and Zuspan’s magnesium sulphate regimens in the management of severe preeclampsia and eclampsia: a prospective observational study. Int J Clin Obstet Gynaecol. 2026;10(4):1287–97.

Dickerson AG, Joseph CA, Kashfi K. Current approaches and innovations in managing preeclampsia: highlighting maternal health disparities. J Clin Med. 2025;14(4):1190.

Wu J, He A. Efficacy of labetalol combined with magnesium sulfate in the treatment of hypertension during pregnancy and its effects on serum PAPPA and PLGF levels. Indian J Pharm Sci. 2024;86(1 Suppl):72–8.

Zhu Y, Zhou Q. Effects of magnesium sulfate and labetalol combined therapy on blood pressure and pregnancy outcomes in early-onset severe preeclampsia. Int J Clin Exp Med. 2017;10(1):1297–1302.

Wang Y, Bao J, Peng M. Effect of magnesium sulfate combined with labetalol on serum sFlt-1/PlGF ratio in patients with early-onset severe pre-eclampsia. Exp Ther Med. 2020;20(6):276.

Gu Z, Gu W, Zhang G, Tang Y, Wang M, Guo Y, et al. Effects of magnesium sulfate combined with labetalol on inflammatory stress and pregnancy outcome of patients with gestational hypertension. Exp Ther Med. 2024;27(6):266.

Ganesh SK, Unnikrishnan B, Nagaraj K, Jayaram S. Determinants of pre-eclampsia: a case-control study in a district hospital in South India. Indian J Community Med. 2010;35(4):502–505.

Kolluru V, Harika RY, Kaul R. Maternal and perinatal outcome associated with pregnancy induced hypertension. Int J Reprod Contracept Obstet Gynecol. 2016;5(10):3367–71.

Gomathy E, Akurati L, Radhika K. Early onset and late onset preeclampsia-maternal and perinatal outcomes in a rural tertiary health center. Int J Reprod Contracept Obstet Gynecol. 2018;7(6):2266–9.

Yadav S, Saxena U, Yadav R, Gupta S. Hypertensive disorders of pregnancy and associated risk factors in urban population. Int J Reprod Contracept Obstet Gynecol. 2017;6(9):4026–30.

Priyamvadha PM, Kala R, Kumar A. Maternal and perinatal outcome in pregnancies complicated by preeclampsia: a hospital based prospective study. Int J Reprod Contracept Obstet Gynecol. 2022;11(6):1691–7.

Jain S, Upadhyay A, Jain PK, Gupta S. Fetomaternal outcome in preeclampsia. Int J Med Sci Public Health. 2014;3(12):1505–8.

Aabidha PM, Cherian AG, Paul E, Helan J. Maternal and fetal outcome in pre-eclampsia in a secondary care hospital in South India. J Family Med Prim Care. 2015;4(2):257–60.